Financial Performance - The company's operating revenue for Q3 2025 was ¥259,174,054.19, representing a decrease of 6.91% compared to the same period last year[4] - The total profit for the quarter was ¥32,127,193.39, down 13.48% year-over-year[4] - The net profit attributable to shareholders was ¥28,262,353.31, reflecting a decline of 13.07% compared to the previous year[4] - The basic earnings per share for the quarter was ¥0.18, a decrease of 35.71% year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥26,451,849.83, down 13.73% year-over-year[4] - Total operating revenue for the first three quarters of 2025 was CNY 725,380,100.62, a decrease of 7.36% compared to CNY 782,935,962.88 in the same period of 2024[16] - Net profit for the first three quarters of 2025 was CNY 76,409,567.27, down 18.24% from CNY 93,456,112.74 in 2024[17] - Basic and diluted earnings per share for the first three quarters of 2025 were both CNY 0.49, compared to CNY 0.80 in the same period of 2024[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,648,349,562.87, an increase of 3.63% from the end of the previous year[5] - Total current assets as of September 30, 2025, amount to ¥1,152,655,856.26, an increase from ¥1,135,151,347.05 at the end of 2024[14] - Total assets amount to ¥1,648,349,562.87, compared to ¥1,590,569,355.28 at the end of 2024[14] - Non-current assets total ¥495,693,706.61, an increase from ¥455,418,008.23 year-over-year[14] - The total liabilities increased to CNY 190,045,784.37 from CNY 170,433,957.25, indicating a growth of 11.06%[15] - Total equity attributable to shareholders rose to CNY 1,458,303,778.50 from CNY 1,420,135,398.03, an increase of 2.68%[15] Cash Flow - The cash flow from operating activities for the year-to-date was ¥110,289,242.62, showing a decrease of 2.09% compared to the previous year[4] - Cash inflow from operating activities totaled CNY 789,040,144.59, a decrease from CNY 872,741,529.71 in the previous year[20] - Cash paid for purchasing goods and services was CNY 483,547,369.83, down from CNY 559,028,673.33 in 2024[20] - The net cash flow from operating activities was $110,289,242.62, a slight decrease from $112,640,151.54 in the previous period[21] - Total cash outflow from operating activities amounted to $678,750,901.97, compared to $760,101,378.17 last year, indicating a reduction of approximately 10.7%[21] - The net cash flow from investing activities was -$81,385,495.06, an improvement from -$178,589,454.79 in the previous period[21] - Cash inflow from investing activities totaled $176,111,969.73, significantly higher than $695,000.00 in the prior year[21] - Cash outflow for investing activities was $257,497,464.79, up from $179,284,454.79, reflecting an increase of approximately 43.6%[21] - Cash flow from financing activities resulted in a net outflow of -$47,535,369.40, compared to -$3,236,500.00 last year[21] - The cash and cash equivalents at the end of the period were $698,495,922.45, a decrease from $157,274,036.10 in the previous year[21] - The total cash and cash equivalents decreased by $21,433,280.90, compared to a decrease of $67,080,769.16 in the previous period[21] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 17,056[11] - The largest shareholder, Chen Guoping, holds 67,743,000 shares, representing 43.43% of total shares[11] Other Information - Non-recurring gains for the quarter totaled ¥1,810,503.48, with a year-to-date total of ¥4,258,760.46[8] - The company reported a decrease in the diluted earnings per share of 38.75% for the year-to-date period[9] - The company has no reported changes in major shareholders due to stock lending activities[12] - The company has not disclosed any new product developments or market expansion strategies in the current report[12] - The company will not apply new accounting standards starting from 2025[22]

Core Viewpoint - The company announced significant governance changes, including a capital restructuring and the cancellation of the supervisory board, which are set to be approved in upcoming meetings [1] Group 1: Governance Changes - The company will hold its second board meeting on August 28, 2025, to review proposals for changing the registered capital and canceling the supervisory board [1] - A temporary shareholders' meeting is scheduled for September 16, 2025, to approve the same proposals regarding capital changes and governance structure [1] - As of the announcement date, the company has completed the necessary business registration procedures for these changes [1]

健尔康医疗科技股份有限公司 章 程 $${\bf\Xi}{\bf\Xi}{\bf O}{\bf\Xi}{\bf\Xi}{\bf\Xi}{\bf\Xi}{\bf\Xi}{\bf\Xi}{\bf\Xi}$$ | | | 第一章 总 则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为, 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、《上海证券交易所股票上市规则》（以 下简称"《上市规则》"）、《上海证券交易所上市公司自律监管指引第 1 号— —规范运作》和其他有关规定，制订本章程。 第二条 健尔康医疗科技股份有限公司（以下简称"公司"）系依照《公司 法》和其他有关规定成立的股份有限公司。 第六条 公司注册资本为人民币 15,600 万元。 第七条 公司为永久存续的股份有限公司。 第八条 代表公司执行公司事务的董事为公司的法定代表人。公司董事长为 公司执行公司事务的董事。 公司以发起方式设立，由有限责任公司整体变更为股份有限公司，并在常州 市 市 场 监 督 管 理 局 注 册 登 记 ， 取 得 营 业 执 照 ， 统 一 社 会 信 ...

证券代码：603205 证券简称：健尔康 公告编号：2025-029 健尔康医疗科技股份有限公司 关于完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 健尔康医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日 召开第二届董事会第十四次会议，审议通过了《关于变更公司注册资本、取消监 事会并修订<公司章程>及其附件的议案》《关于修订和制定部分治理制度的议案》， 2025 年 9 月 16 日公司召开 2025 年第一次临时股东大会审议通过《关于变更公 司注册资本、取消监事会并修订<公司章程>及其附件的议案》《关于修订和制定 部分治理制度的议案》。相关内容详见公司于 2025 年 8 月 29 日及 2025 年 9 月 17 日在上海证券交易所网站（www.sse.com.cn）以及《上海证券报》《中国证 券报》《证券时报》《证券日报》《经济参考网》披露的相关公告。 截至本公告披露日，公司已完成上述工商备案登记手续，变更后的登记信息 如下: 名称:健尔康医疗科技股份有限公司 许可项目: ...

Core Viewpoint - The company Jianerkang experienced a slight decline in stock price and reported specific financial metrics related to its trading activities and business performance [1][2]. Group 1: Trading Activity - On October 13, Jianerkang's stock price fell by 0.74%, with a trading volume of 23.36 million yuan [1]. - The financing buy-in amount for Jianerkang on the same day was 3.83 million yuan, while the financing repayment was 2.88 million yuan, resulting in a net financing buy-in of 0.95 million yuan [1]. - As of October 13, the total financing and securities lending balance for Jianerkang was 74.94 million yuan, with the financing balance accounting for 6.81% of the circulating market value [1]. Group 2: Company Overview - Jianerkang Medical Technology Co., Ltd. is located in Jintan District, Changzhou, Jiangsu Province, and was established on June 6, 2000, with its listing date set for November 7, 2024 [1]. - The company's main business involves the research, production, and sales of disposable medical devices and disinfectant hygiene products, with revenue composition as follows: nursing products 33.19%, surgical consumables 30.64%, polymer and auxiliary products 18.46%, disinfecting and cleaning products 16.93%, and others 0.79% [1]. Group 3: Financial Performance - As of June 30, Jianerkang had 18,200 shareholders, a decrease of 0.22% from the previous period, with an average of 1,650 circulating shares per person, an increase of 0.22% [2]. - For the first half of 2025, Jianerkang reported operating revenue of 466 million yuan, a year-on-year decrease of 7.60%, and a net profit attributable to shareholders of 48.15 million yuan, down 21.00% year-on-year [2]. - Since its A-share listing, Jianerkang has distributed a total of 42.12 million yuan in dividends [2].

Core Viewpoint - The company emphasizes the importance of accounts receivable management and maintains a strong focus on operational efficiency and long-term value despite short-term performance fluctuations [1] Group 1: Accounts Receivable Management - All customers are assigned dedicated sales personnel for tracking services and payment collection, with performance evaluations strictly linked to payment recovery [1] - The company has a risk control specialist who organizes monthly meetings to discuss accounts receivable balances and overdue payments, ensuring a structured approach to payment collection [1] Group 2: Financial Performance and Valuation - The company maintains a net profit margin above 10% for the first half of 2025, despite facing short-term performance volatility [1] - The management believes the current valuation is reasonable, reflecting the company's position as a leading exporter of medical dressings in China [1] Group 3: Strategic Initiatives and Market Position - The company is committed to advancing new project implementations and expediting the production launch of its Vietnam factory to achieve annual targets [1] - There is confidence in the company's long-term value due to favorable industry policies, accelerated international expansion, and ongoing collaborations with major global players like Cardinal and Medline [1]

Core Viewpoint - The company, Jianerkang Medical Technology Co., Ltd., is set to hold a half-year performance briefing on October 10, 2025, to discuss its operational results and financial status for the first half of 2025, allowing investors to engage in Q&A sessions [2][3][4]. Group 1: Meeting Details - The performance briefing will take place on October 10, 2025, from 11:00 AM to 12:00 PM [2][4]. - The meeting will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][3]. - Investors can submit questions from September 25, 2025, to October 9, 2025, before 4:00 PM, through the Roadshow Center website or via the company's email [2][5]. Group 2: Company Representatives - The meeting will feature key company representatives, including Chairman and General Manager Chen Guoping, Board Secretary Liu Ping, and Chief Financial Officer Gong Xiaole [4][5]. - Adjustments to the attending personnel may occur due to special circumstances [4]. Group 3: Post-Meeting Information - After the briefing, investors can access the meeting's details and main content through the Shanghai Stock Exchange Roadshow Center [5].

证券代码：603205 证券简称：健尔康 公告编号：2025-028 健尔康医疗科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半 年度的经营成果及财务指标的具体情况与投资者进行互动交流和沟 通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一）会议召开时间：2025年10月10日（星期五）11:00-12:00 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 三、 参加人员 董事长、总经理：陈国平先生 投资者可于 2025 年 09 月 25 日 （星期四） 至 10 月 09 日 （星 期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过公司邮箱 lp@chinajek.com 进行提问。公司将 ...

Company Overview - Full Name: Jianerkang Medical Technology Co., Ltd [1] - Abbreviation: Jianerkang [1] - Stock Code: 603205.SH [1] - IPO Application Date: June 22, 2022 [1] - Listing Date: November 7, 2024 [1] - Listing Board: Shanghai Stock Exchange Main Board [1] - Industry: Specialized Equipment Manufacturing [1] - IPO Sponsor: CITIC Jianan Securities [1] - Legal Advisor: Shanghai Guangfa Law Firm [1] - Audit Firm: Tianheng Accounting Firm (Special General Partnership) [1] Regulatory and Performance Evaluation - Disclosure Situation: Required to clarify compliance with main board positioning and regulatory requirements [1] - Regulatory Penalties: No deductions [2] - Public Supervision: No deductions [2] - Listing Cycle: Jianerkang's listing cycle is 869 days, exceeding the average of 629.45 days for 2024 A-share companies [2] - Multiple Applications: Not applicable, no deductions [3] - Issuance Costs: Underwriting and sponsorship fees amount to 26.95 million yuan, with a commission rate of 6.13%, lower than the average of 7.71% [3] Market Performance - First Day Performance: Stock price increased by 378.36% on the first day of listing [4] - Three-Month Performance: Stock price increased by 152.42% within three months post-listing [5] - Issuance Price-Earnings Ratio: Jianerkang's issuance P/E ratio is 14.59 times, significantly lower than the industry average of 26.68 times, representing 54.69% of the industry average [6] Fundraising and Financial Performance - Actual Fundraising: Expected to raise 774 million yuan, but actual fundraising was 440 million yuan, a decrease of 43.20% [7] - Short-term Performance Post-Listing: In 2024, the company's revenue increased by 1.18% year-on-year, while net profit attributable to shareholders decreased by 2.69%, and non-recurring net profit decreased by 4.41% year-on-year [8] - Abandonment Rate: The abandonment rate is 0.41% [8] Overall Evaluation - Total Score: Jianerkang's IPO project received a total score of 83, classified as Grade B [8] - Negative Factors Impacting Score: Disclosure quality needs improvement, listing cycle exceeds two years, significant reduction in actual fundraising, decline in net profit in the first accounting year, and abandonment rate of 0.41% [8]

证券代码：603205 证券简称：健尔康 公告编号：2025-025 健尔康医疗科技股份有限公司 第二届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 二、监事会会议审议情况 经全体监事审议，会议表决情况如下： （一）审议通过《关于免去监事会主席职务的议案》 根据《中华人民共和国公司法》《关于新＜公司法＞配套制度规则实施相关过渡期安排》《上市公司章 程指引》等相关法律法规的规定，结合公司实际情况，公司将不再设置监事会和监事，免去汤红芳女士 监事会主席的职务。 表决结果：3票同意，0票反对，0票弃权。 特此公告。 健尔康医疗科技股份有限公司 一、 监事会会议召开情况 健尔康医疗科技股份有限公司（以下简称"公司"）第二届监事会第九次会议于2025年9月16日以现场方 式在公司会议室召开，会议通知于2025年9月12日以书面等方式送达。本次会议由监事会主席汤红芳女 士主持，会议应到监事3人，实到监事3人。本次监事会的召集、召开和表决程序符合《中华人民共和国 公司法》等有关法律法规及《健尔康医疗科技股份有限公 ...